Tandem Investment Advisors Inc. lessened its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 1.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 364,709 shares of the medical instruments supplier's stock after selling 3,642 shares during the period. Becton, Dickinson and Company makes up about 2.9% of Tandem Investment Advisors Inc.'s holdings, making the stock its 18th biggest holding. Tandem Investment Advisors Inc. owned 0.13% of Becton, Dickinson and Company worth $83,540,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also bought and sold shares of the company. Brighton Jones LLC grew its stake in Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Becton, Dickinson and Company by 50.6% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 82,110 shares of the medical instruments supplier's stock worth $18,808,000 after acquiring an additional 27,581 shares during the last quarter. Foster Victor Wealth Advisors LLC bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $6,406,000. GAMMA Investing LLC lifted its holdings in shares of Becton, Dickinson and Company by 29.9% in the 1st quarter. GAMMA Investing LLC now owns 3,250 shares of the medical instruments supplier's stock worth $744,000 after acquiring an additional 748 shares during the last quarter. Finally, Ritholtz Wealth Management bought a new stake in shares of Becton, Dickinson and Company in the 1st quarter worth approximately $224,000. Hedge funds and other institutional investors own 86.97% of the company's stock.
Becton, Dickinson and Company Trading Down 0.6%
NYSE BDX traded down $1.11 during trading on Friday, hitting $176.16. The company had a trading volume of 1,057,606 shares, compared to its average volume of 2,058,031. The company has a current ratio of 1.13, a quick ratio of 0.64 and a debt-to-equity ratio of 0.70. Becton, Dickinson and Company has a one year low of $163.33 and a one year high of $251.99. The company has a market cap of $50.49 billion, a price-to-earnings ratio of 33.62, a price-to-earnings-growth ratio of 1.33 and a beta of 0.25. The company's fifty day moving average is $173.94 and its 200-day moving average is $207.80.
Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $3.35 EPS for the quarter, topping the consensus estimate of $3.28 by $0.07. Becton, Dickinson and Company had a net margin of 7.28% and a return on equity of 15.99%. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the business earned $3.17 EPS. The company's revenue for the quarter was up 4.5% on a year-over-year basis. On average, sell-side analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.
Becton, Dickinson and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, June 30th. Shareholders of record on Monday, June 9th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, June 9th. This represents a $4.16 annualized dividend and a yield of 2.36%. Becton, Dickinson and Company's dividend payout ratio (DPR) is presently 79.39%.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently weighed in on BDX shares. Barclays lowered their price objective on shares of Becton, Dickinson and Company from $261.00 to $241.00 and set an "overweight" rating for the company in a report on Tuesday, June 3rd. Raymond James Financial lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Friday, May 2nd. William Blair lowered shares of Becton, Dickinson and Company from an "outperform" rating to a "market perform" rating in a report on Thursday, May 1st. Stifel Nicolaus lowered their price target on shares of Becton, Dickinson and Company from $280.00 to $224.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Finally, Piper Sandler lowered shares of Becton, Dickinson and Company from an "overweight" rating to a "neutral" rating and lowered their price target for the company from $260.00 to $185.00 in a report on Friday, May 2nd. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus target price of $219.22.
Get Our Latest Stock Report on Becton, Dickinson and Company
Insider Activity
In related news, EVP David Shan sold 1,166 shares of the stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $171.19, for a total value of $199,607.54. Following the completion of the transaction, the executive vice president directly owned 4,575 shares in the company, valued at $783,194.25. This trade represents a 20.31% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael David Garrison sold 479 shares of the stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $197.28, for a total transaction of $94,497.12. Following the completion of the transaction, the executive vice president owned 4,887 shares of the company's stock, valued at approximately $964,107.36. The trade was a 8.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.36% of the stock is owned by company insiders.
About Becton, Dickinson and Company
(
Free Report)
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Further Reading
Before you consider Becton, Dickinson and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Becton, Dickinson and Company wasn't on the list.
While Becton, Dickinson and Company currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
